About Redx Pharma
Redx Pharma is a company based in Liverpool (United Kingdom) founded in 2010 was acquired by Redmile Group in May 2020. Redx Pharma offers products and services including Zelasudil, RXC008, and Zamaporvint. Redx Pharma operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Liverpool, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Redx Pharma Plc
- Date of Incorporation 07 Sep, 2010
- Jurisdiction MACCLESFIELD, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$17.18 M (USD), Post-IPO
Oct 18, 2023
-
Investors
Polar Capital
& 6 more
-
Employee Count
Not available
-
Acquired by
Redmile Group
(May 01, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Redx Pharma
Redx Pharma offers a comprehensive portfolio of products and services, including Zelasudil, RXC008, and Zamaporvint.
Treats interstitial lung diseases and fibrotic indications effectively.
Targets fibrostenotic Crohn’s disease with GI-restricted action.
Focuses on Wnt-ligand driven cancers as targeted therapy.
People of Redx Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Redx Pharma
Investors in Redx Pharma
Redx Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Polar Capital, Sofinnova Partners and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Private equity investments are directed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Redx Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Redx Pharma
Investment portfolio details for Redx Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Redx Pharma
Detailed financials for Redx Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Redx Pharma Comparisons
Peer comparison for Redx Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Redx Pharma
Redx Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
Detailed competitors of Redx Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Redx Pharma
Complete news archive for Redx Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Redx Pharma
Redx Pharma was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Redx Pharma is headquartered in Liverpool, United Kingdom.
Redx Pharma was founded in 2010 and is based in Liverpool, United Kingdom. Small molecule therapeutics are developed by the company targeting cancer, infectious diseases, and autoimmune conditions within the pharmaceutical sector. Operations center on drug discovery and early-stage development, with a focus on innovative treatments. The companys online presence is maintained at redxpharma.com, supporting investor and stakeholder engagement.
Redx Pharma's top competitors include Merck, Roivant Sciences and Amgen.
Redx Pharma offers Zelasudil, RXC008, and Zamaporvint.
Redx Pharma has 7 investors. Key investors include Polar Capital, Sofinnova Partners, Invus, Redmile Group, and Polar Capital.